Expert Discusses Bipolar Androgen Therapy Plus PARP Inhibition for Castration-Resistant Prostate Cancer
CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.